A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated RejectionKatharina A. Mayer, Georg A. Böhmig, Alexander Kainz et al.|New England Journal of Medicine|2024Cited by 151
Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammationMatthias Diebold, Georg A. Böhmig, Hannes Vietzen et al.|American Journal of Transplantation|2023Cited by 26
Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort StudyMatthias Diebold, Georg A. Böhmig, Hannes Vietzen et al.|Transplantation|2024Cited by 13
225.3: Randomized phase 2 trial of felzartamab in humoral transplant rejection.Katharina A. Mayer, Georg A. Böhmig, Eva Schrezenmeier et al.|Transplantation|2024Cited by 0